This article covers Isomorphic Labs, a London‑headquartered biotech startup that has raised £3.8bn in an oversubscribed growth funding round co‑led by Greenoaks and Sequoia Capital. The funding is intended to scale its IsoDDE drug design engine, advance AI‑designed therapeutic candidates into clinical development and build AI‑first translational and clinical infrastructure, supporting AI‑driven drug discovery and the UK life sciences sector.
Isomorphic Labs, a London-headquartered biotech startup led by Demis Hassabis, has raised £3.8 billion in an oversubscribed growth funding round co‑led by Greenoaks and Sequoia Capital. The capital will be used to scale its IsoDDE drug design engine, advance a pipeline of AI‑designed therapeutic candidates through preclinical work and towards clinical trials, and build AI‑first translational and clinical development infrastructure — a significant vote of confidence for AI‑driven drug discovery out of the UK.
A £3.8 billion growth round is among the largest ever raised by a UK‑based life sciences company and signals sustained investor appetite for AI‑first drug discovery. The size and composition of the investor group — including repeat backing from Alphabet‑linked funds and participation from public and sovereign investors — underlines strategic interest in companies that combine machine learning with drug development. If Isomorphic can translate its preclinical advances into clinical candidates, the payout could accelerate timelines that traditionally take many years and reshape where early drug design takes place.
Isomorphic’s core offering is IsoDDE, a unified drug design engine that layers multiple foundational simulation AI models to operate across therapeutic areas and drug modalities. According to the company, IsoDDE explores chemical space, designs and refines molecules for drug‑like properties, and uses proprietary agents to reason over complex biological systems. That platform underpins both wholly owned internal programmes and partnered discovery collaborations.
The company reports positive preclinical results in oncology and immunology for internal programmes and partner work, positioning some programmes to move into clinical entry. Proceeds from the round are earmarked to mature IsoDDE further, expand model capabilities into new biology, deepen mechanistic disease understanding through partner ecosystems, and build global infrastructure for AI‑led bioengineering and clinical development.
The round was co‑led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and other new investors. Alphabet continued to contribute significantly through its venture groups, and all existing backers took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company described the round as oversubscribed.
The investor mix combines deep venture capital resources, strategic corporate capital from Alphabet affiliates, large sovereign and institutional investors, and high‑profile new investors. That blend gives Isomorphic both long‑term funding runway and access to technical and commercial partners as it attempts the high‑risk, high‑reward work of turning AI outputs into regulated medicines.
In the announcement, Neil Mehta, Founding Partner at Greenoaks, said:
Discovering and developing new medicines is an optimization challenge of almost infinite scale. Isomorphic is transforming that journey, building deep learning systems that can predict complex biological behaviors with remarkable accuracy and systematically map the path to new medicines. We believe Demis, Max, and the Isomorphic team are building the future of AI‑led drug discovery and we are proud to partner with them on this essential mission.
In the announcement, Konstantine Buhler, Partner at Sequoia Capital, said:
Isomorphic Labs is building foundational technology for the future of medicine. It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co‑lead this round and help further scientific discovery in medicine.
If you're researching potential backers in this space:
Isomorphic was founded in 2021 and operates from London, with offices in Cambridge, Massachusetts and Lausanne. The company says it is advancing its portfolio through a mix of partnered and wholly owned programmes while investing in infrastructure to move molecules into human testing.
In the announcement, Demis Hassabis, Co‑founder & CEO at Isomorphic Labs, said:
When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI. Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.
In the announcement, Max Jaderberg, President at Isomorphic Labs, said:
Every week we are making repeatable scientific advancements enabled by our models. These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery. Our interdisciplinary teams combine world‑leading machine learning researchers with top‑class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades. We are translating our discoveries directly into potential life‑changing medicines, built on the infrastructure we are establishing for the future of bioengineering with this investor backing.
This round highlights two broader trends in the UK and European ecosystem: deep investor conviction in AI applied to life sciences, and continued willingness from both private and public funds to back capital‑intensive bets. The participation of the UK Sovereign AI Fund and major international backers points to strategic and geopolitical interest in keeping high‑value AI and drug discovery work rooted in the UK.
That said, translating AI‑designed molecules into approved medicines remains a long, uncertain path that requires clinical validation and regulatory success. The funding gives Isomorphic an unusually large runway to test that hypothesis; the sector and public stakeholders will be watching whether the platform shortens timelines and improves success rates in first‑in‑human trials.
Overall, the round is a signal that investors are prepared to place very large bets on companies combining advanced machine learning with drug discovery — and that the UK continues to be a major node in that global effort.
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
![]() Greenoaks( ) | Generalist | |||
![]() Sequoia Capital( ) Sequoia Capital specialises in investing in daring companies within technology s... Menlo Park, US | ||||
![]() a16z( ) This venture capital firm focuses on sectors such as AI, Bio + Health, Consumer,... San Francisco, US | ||||
![]() Alphabet( ) Mountain View, US | ||||
![]() Thrive Capital( ) New York, United States | ||||
![]() Google Ventures( ) GV (Google Ventures), established in 2009, invests in technology-driven companie... London | ||||
![]() CapitalG( ) San Francisco, US | ||||
![]() Temasek( ) Singapore, Singapore | ||||
![]() | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK